Richard Wang is the founder of Neukio Biotherapeutics. Neukio Biotherapeutics has raised $90M in total funding. Latest round: Series A.
Richard Wang is the founder, chairman, and CEO of Neukio Biotherapeutics, an innovative biotherapeutic company established in June 2021 in Shanghai, China. Neukio focuses on developing next-generation immune cell therapies, specifically iPSC-derived off-the-shelf CAR-NK cell therapy products for solid tumors. The company has successfully raised $50 million in a Series A-1 funding round and $40 million in an Angel round. Wang's prior background includes serving as the founding CEO of Fosun Kite Biotechnology, where he brought China's first CAR-T cell therapy, Yescarca, to market.
Full founder directory · Investor directory · Company funding database · Fundraising library